Latest news with #BlueOwl
Yahoo
15-07-2025
- Business
- Yahoo
Private Credit Boom Isn't Over: Blue Owl Co-President
JPMorganChase CEO Jamie Dimon says the private lending industry may have hit a plateau. But Craig Packer, co-president and head of Credit at Blue Owl, disagrees. He joined Wall Street Beat on "Bloomberg Open Interest" to talk about the growth of private credit.
Bloomberg
15-07-2025
- Business
- Bloomberg
Blue Owl: Wealthy Investors Want Access to Alternatives
James Clarke, global head of institutional capital at Blue Owl, discusses the firm's expansion in the Middle East, investing to withstand geopolitical shocks and cyclical bumps, and providing individual investors access to alternative assets. (Source: Bloomberg)
Bloomberg
15-07-2025
- Business
- Bloomberg
Nvidia Prepares China Sales Resumption; EU Eyes Tariff Retaliation
US equity futures gain as Nvidia rises in the pre-market after the chip giant said the US would approve sales of it's H20 AI chips to Chinese customers. The EU eyes Boeing, bourbon and US autos in a potential retaliation against US tariffs. JPMorgan, Citi and Wells Fargo kick off earnings season. Peter Oppenheimer of Goldman Sachs says the US stock market is still very concentrated with big tech distorting the overall S&P 500 index. James Clarke of Blue Owl says investors in private credit are looking to opportunities that can withstand geopolitical shocks or cyclical bumps. France's Minister of European Affairs Benjamin Haddad says the EU finds US tariffs unacceptable and stands ready to retaliate with resolve. 'Bloomberg Brief' delivers the market news, data and analysis you need to set your agenda. (Source: Bloomberg)
Yahoo
07-07-2025
- Business
- Yahoo
Blue Owl Capital Launches U.S. Diversified Direct Lending Strategy with Australia's Koda Capital
Blue Owl Credit Income Fund AUT (OCIC-A) now available to Australian financial advisors and their clients in partnership with Australia's largest independent wealth management firm. NEW YORK and SYDNEY, July 8, 2025 /PRNewswire/ -- Blue Owl Capital Inc. ("Blue Owl") (NYSE: OWL), a leading alternative asset manager, announced the launch of Blue Owl Credit Income Fund AUT ("OCIC-A" or "the fund"), an Australian unit trust, in partnership with Koda Capital. The strategy is available to Australian financial advisors and their wholesale clients, underscoring Blue Owl's commitment to serving Australia's most sophisticated investors. The partnership with Koda Capital, Australia's largest independent wealth management firm, is a cornerstone of Blue Owl's strategic entry into the region. With over A$14 billion in client assets under management, Koda is widely recognized for its unwavering commitment to client-first, conflict-free advice. The firm has earned accolades such as the Australian Financial Review's "Best Private Wealth Manager" and is celebrated for its leadership in offering innovative investment solutions to the Australian private wealth channel. The fund invests in Blue Owl Credit Income Corp (OCIC), a private credit solution that seeks to generate attractive, income-based returns through a diversified portfolio of predominantly senior secured, directly originated floating rate loans to U.S. middle and upper middle-market companies. The strategy is designed to provide consistent income and capital preservation, making it a compelling solution for investors seeking high-quality private credit exposure. With significant scale and a broadly diversified portfolio across industries and borrowers, OCIC is well-positioned to access high-quality deal flow, reduce concentration risk, and deliver stable, risk-adjusted returns to investors. The fund provides access to Blue Owl's market-leading direct lending capabilities, enabling Koda clients to diversify their portfolios with institutional-grade private credit strategies. The offering is designed to meet the growing demand for differentiated, global alternatives among high-net-worth and sophisticated investors in Australia. Sean Connor, President & CEO of Global Private Wealth at Blue Owl, commented: "Partnering with Koda Capital is a significant step in our global expansion strategy. Koda's reputation for excellence and innovation aligns perfectly with Blue Owl's mission to deliver institutional-quality private market solutions to the wealth channel. We're excited to bring OCIC-A to Australian advisers and their clients, offering access to a differentiated, high-quality direct lending strategy." Jonathan Ayres, Managing Partner at Koda Capital, said: "At Koda, our independence gives us the freedom to search globally and select only the most compelling investment strategies for our clients. Seeding this feeder fund reflects our commitment to accessing institutional-grade opportunities on competitive terms delivered locally and tailored for Australian investors." Channel Capital's subsidiary, Channel Investment Management Limited (CIML), acts as the Responsible Entity for the fund, overseeing essential services such as compliance, risk management, fund administration, custody, financial reporting, and investor services. CIML works with a select group of clients and funds, covering traditional, alternative and private market strategies, with deep expertise in structuring and managing Australian feeder funds for global investment managers. Channel Capital services A$57 billion in assets on behalf of its partners, as of 31 March 2025. About Blue Owl Blue Owl (NYSE: OWL) is a leading asset manager that is redefining alternatives®. With $273 billion in assets under management as of March 31, 2025, we invest across three multi-strategy platforms: Credit, Real Assets, and GP Strategic Capital. Anchored by a strong permanent capital base, we provide businesses with private capital solutions to drive long-term growth and offer institutional investors, individual investors, and insurance companies differentiated alternative investment opportunities that aim to deliver strong performance, risk-adjusted returns, and capital preservation. Together with over 1,200 experienced professionals globally, Blue Owl brings the vision and discipline to create the exceptional. To learn more, visit To find out more about OCIC-A, visit About Koda Capital Koda Capital is Australia's leading independent wealth management firm, and provides advice to high-net-worth individuals, families, and not-for-profits. With over $14 billion in funds under management (FUM), it delivers tailored investment and strategic wealth solutions that put clients' interests first. Founded in 2014, Koda has more than 50 Partners and has offices in Sydney, Melbourne, Perth and Brisbane, and offers expertise across Investment Strategy, Philanthropy & Social Capital, Structuring & Tax, and Family Leadership. Its independence ensures it remains free from institutional conflicts, allowing it to provide objective, client-focused advice. It is committed to delivering sophisticated investment opportunities, strategic insights, and long-term wealth solutions to help its clients achieve their financial goals. To learn more, visit Forward Looking Statements Certain statements made in this release are "forward looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. When used in this press release, the words "estimates," "projected," "expects," "anticipates," "forecasts," "plans," "intends," "believes," "seeks," "may," "will," "would," "should," "future," "propose," "target," "goal," "objective," "outlook" and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. Any such forward-looking statements are made pursuant to the safe harbor provisions available under applicable securities laws and speak only as of the date made. Blue Owl assumes no obligation to update or revise any such forward-looking statements except as required by law. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Blue Owl's control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others, that may affect actual results or outcomes include the inability to recognize the anticipated benefits of strategic acquisitions; costs related to acquisitions; the inability to maintain the listing of Blue Owl's shares on the New York Stock Exchange; Blue Owl's ability to manage growth; Blue Owl's ability to execute its business plan and meet its projections; potential litigation involving Blue Owl; changes in applicable laws or regulations; and the possibility that Blue Owl may be adversely affected by other economic, business, geo-political and competitive factors. Investor Contact Ann DaiHead of Investor Relationsblueowlir@ Media Contact Nick TheccanatPrincipal, Corporate Communications & Government View original content: SOURCE Blue Owl Capital Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
30-06-2025
- Business
- Associated Press
BridgeBio Raises $300 Million Through Partial Capped Monetization of BEYONTTRA® European Royalty
PALO ALTO, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ('BridgeBio' or the 'Company'), a new type of biopharmaceutical company focused on genetic diseases, today announced it has sold a portion of royalties due to the Company from sales of BEYONTTRA in Europe to HealthCare Royalty ('HCRx') and funds managed by Blue Owl Capital ('Blue Owl') for $300 million. This royalty financing agreement monetizes select anticipated royalties and provides immediate less-dilutive capital to the Company. 'We're excited to partner with HCRx and Blue Owl to strengthen our balance sheet in support of the launch of Attruby and our pipeline of first and best-in-class genetic medicines. This transaction preserves significant upside for our shareholders, with careful structuring that limits annual as well as total payments made to the royalty investors. This financing highlights the strong early start and large global potential of acoramidis,' said Chinmay Shukla, Senior Vice President of Strategic Finance at BridgeBio. Clarke Futch, Chairman and Chief Executive Officer of HCRx commented: 'We have been following the progress of acoramidis for years and strongly believe in its potential to positively impact the lives of patients living with ATTR-CM. This investment exemplifies HCRx's commitment to supporting innovation in the biopharmaceutical industry and we are pleased to collaborate with BridgeBio on this transaction.' 'We are pleased to continue our support of BridgeBio through this royalty monetization transaction,' said Sandip Agarwala, Managing Director and Head of Life Sciences at Blue Owl. 'This investment reflects our confidence in BEYONTTRA commercial potential and our commitment to providing flexible capital solutions that help advance life-saving therapies.' Under the terms of the agreement, BridgeBio has received $300 million from HCRx and Blue Owl managed funds in exchange for 60% of royalties on the first $500 million of annual BEYONTTRA net sales in Europe. The agreement includes an initial cap of 1.45x. Once the applicable cap is met, no further payments will be owed to the investors. In March 2024, BridgeBio entered into an exclusive licensing agreement with Bayer Consumer Care AG to commercialize BEYONTTRA in Europe for the treatment for ATTR‑CM. To date, BridgeBio has received $210 million in upfront and regulatory milestones, and anticipates receiving a further $75 million in near-term milestone payments, along with tiered royalties starting in the low‑30% range on net sales of BEYONTTRA in Europe. Acoramidis is approved in the U.S. as Attruby by the FDA and in Europe as BEYONTTRA by the European Commission. It is also approved as BEYONTTRA by the Japanese Pharmaceuticals and Medical Devices Agency, and UK Medicines and Healthcare Products Regulatory Agency with all labels specifying near-complete stabilization of TTR. Latham & Watkins LLP served as legal advisor to BridgeBio. Gibson, Dunn & Crutcher LLP served as legal advisor to HCRx and Blue Owl. About BEYONTTRA BEYONTTRA is an orally administered near-complete (≥90%) stabilizer of transthyretin (TTR) indicated for the treatment of wild-type or variant transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM). For full prescribing information, please refer to the Summary of Product Characteristics (SmPC) on the Medicines and Healthcare products Regulatory Agency website at About Attruby™ (acoramidis) INDICATION Attruby is a transthyretin stabilizer indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization. IMPORTANT SAFETY INFORMATION Adverse Reactions Diarrhea (11.6% vs 7.6%) and upper abdominal pain (5.5% vs 1.4%) were reported in patients treated with Attruby versus placebo, respectively. The majority of these adverse reactions were mild and resolved without drug discontinuation. Discontinuation rates due to adverse events were similar between patients treated with Attruby versus placebo (9.3% and 8.5%, respectively). About BridgeBio Pharma, Inc. BridgeBio Pharma, Inc. (BridgeBio) is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio's pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit and follow us on LinkedIn, Twitter,Facebook, and YouTube. About HealthCare Royalty HealthCare Royalty (HCRx) is a leading royalty acquisition company focused on commercial or near-commercial biopharmaceutical products. With offices in Stamford, Conn., San Francisco, Boston, London and Miami, HCRx has invested $5+ billion in over 90 biopharmaceutical products since inception. For more information, visit HEALTHCARE ROYALTY® and HCRx® are registered trademarks of HealthCare Royalty Management, LLC. About Blue Owl Blue Owl (NYSE: OWL) is a leading asset manager that is redefining alternatives®. With $273 billion in assets under management as of March 31, 2025, we invest across three multi-strategy platforms: Credit, Real Assets, and GP Strategic Capital. Anchored by a strong permanent capital base, we provide businesses with private capital solutions to drive long-term growth and offer institutional investors, individual investors, and insurance companies differentiated alternative investment opportunities that aim to deliver strong performance, risk-adjusted returns, and capital preservation. Together with over 1,200 experienced professionals globally, Blue Owl brings the vision and discipline to create the exceptional. To learn more, visit BridgeBio Pharma, Inc. Forward-Looking Statements This press release contains forward-looking statements. Statements in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (the 'Securities Act'), and Section 21E of the Securities Exchange Act of 1934, as amended (the 'Exchange Act'), which are usually identified by the use of words such as 'anticipates,' 'believes,' 'could,' 'estimates,' 'expects,' 'hopes,' 'intends,' 'may,' 'plans,' 'potential,' 'projects,' 'seeks,' 'should,' 'will,' and variations of such words or similar expressions. BridgeBio intends these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act. These forward-looking statements, including statements regarding the potential commercial performance of BEYONTTRA in Europe and other global markets; the anticipated benefits of the royalty monetization agreement with HCRx and Blue Owl Capital; BridgeBio's expectations for the launch and market uptake of Attruby and BEYONTTRA; the belief in acoramidis' ability to positively impact the lives of patients with ATTR-CM; and the expected use of proceeds to support BridgeBio's pipeline of genetic medicines, reflect BridgeBio's current views about its plans, intentions, expectations, and strategies, which are based on information currently available and assumptions it has made. Although BridgeBio believes that its plans, intentions, expectations, and strategies as reflected in or suggested by these forward-looking statements are reasonable, it can give no assurance that such plans, intentions, expectations, or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a number of risks, uncertainties, and assumptions, including, but not limited to: BridgeBio's dependence on third parties for development or commercialization activities; regulatory authorities requiring additional studies or data to support the continued or expanded commercialization of acoramidis; whether data and results meet applicable regulatory requirements or are sufficient for continued development, review, or approval; and whether other regulatory agencies agree with BridgeBio's strategies or data interpretations. These risks also include impacts from global health emergencies, such as delays in regulatory reviews and other activities, manufacturing and supply chain interruptions, adverse effects on healthcare systems, and disruption of the global economy; and the impacts of macroeconomic and geopolitical events, including changing conditions from hostilities in Ukraine and in Israel and the Gaza Strip, increasing inflation rates, and fluctuating interest rates on BridgeBio's operations and expectations. Additional risks are described in the 'Risk Factors' section of BridgeBio's most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q, and other filings with the U.S. Securities and Exchange Commission. Moreover, BridgeBio operates in a highly competitive and rapidly evolving industry in which new risks may emerge from time to time. These forward-looking statements are based upon the current expectations and beliefs of BridgeBio's management as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in these statements. Except as required by applicable law, BridgeBio assumes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events, or otherwise. BridgeBio Media Contact: Bubba Murarka, Executive Vice President [email protected] (650)-789-8220 BridgeBio Investor Contact: Chinmay Shukla, Senior VP Strategic Finance [email protected]
